Furosemide Management for Fluid Retention

Patient Monitoring and Dosing

The American College of Cardiology recommends that patients weigh themselves daily at the same time, preferably in the morning after voiding, and adjust their furosemide dose based on weight changes beyond a specified range, typically increasing the dose by 20-40 mg when weight increases by 2-3 kg above their target "dry weight" 1, 2
Patients should record their weight in a log or diary and identify their target "dry weight", which is the weight at which they have no signs of fluid retention, such as ankle swelling or shortness of breath 1, 2, 3
The American Heart Association suggests that patients expect a weight loss of 0.5-1.0 kg daily once diuresis begins, and continue the increased dose until weight returns to within 1-2 kg of dry weight 1, 2, 3

The American College of Cardiology advises against taking additional furosemide if systolic blood pressure is below 90-100 mmHg, or if experiencing dizziness, lightheadedness, or feeling faint 4
Patients on PRN furosemide must monitor for signs of excessive diuresis, such as dizziness when standing, extreme thirst, dark concentrated urine, and confusion, as well as signs of persistent fluid overload despite treatment, such as worsening shortness of breath or progressive leg swelling 1, 3
Laboratory monitoring should include electrolytes, such as potassium, sodium, and magnesium, checked every 1-3 months for stable patients, or more frequently if doses are being adjusted 1, 3

The American College of Cardiology recommends limiting sodium to 2-3 grams daily, avoiding adding salt to food, and minimizing processed foods to reduce the risk of diuretic resistance 1, 2, 3

Some patients may respond more favorably to torsemide or bumetanide due to superior oral absorption and longer duration of action, which may provide more predictable responses for PRN dosing 1, 2, 3